Rhythm Biosciences (ASX: RHY) share price soars 1300% in 6 months

The Rhythm Bioscience share price continues to push its way up. We take a closer look at what's driving the company's mammoth gains.

| More on:
Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price roared over 12% higher yesterday to close at $1.18. Over the past six-month period, the Rhythm Biosciences share price has thundered over a staggering 1,300%.

Rhythm Biosciences share price hits record high

Just over a week ago, the Rhythm Biosciences share price hit a record high. This gain was following two positive December announcements. The first announcement related to the company appointing a manufacturer for its ColoSTAT product. 

ColoSTAT is a minimally invasive blood test that supports the early detection of bowel cancer. Colorectal cancer is presently the second biggest cause of cancer death in the world and continues to grow.

The second announcement also pertained to ColoSTAT, this time in the shape of a US patent grant. Expansion into the US market resulted in the Rhythm Biosciences technology being accessible to nearly 800 million people worldwide.

During 2020, the Rhythm Biosciences share price rocketed over 640%. The company's current market cap is $210.6 million.

The ColoSTAT technology

The Rhythm Biosciences ColoSTAT technology is being developed as an alternative screening option for people who do not elect to participate in presently available screening options for personal, cultural, or clinical reasons.

According to Rhythm Biosciences, the technology behind this new blood test is designed to be cost effective, minimally invasive, easily run by laboratories and comparable, if not better, than current tests that are purposed to detect early stage colorectal cancer. 

Rhythm Biosciences believes that its technology has the potential to save both lives as well as public health costs. 

A global market focus 

In response to the December approval of the US patent grant for ColoSTAT, Rhythm Biosciences had the following to say about the opportunity presented:

The US represents one of the largest diagnostic markets in the world. The addition of a US patent sees Rhythm expand its global footprint and ultimately, access to a global addressable screening market of close to 800 million people.

In the US, the current 50-74-year-old screening eligible population is approximately 94 million people. This market could grow in the short term by a further 21%, following the US Preventative Services Task Force recommendation that the colorectal cancer screening age be reduced, beginning at 45 years. As a result, where the expansion in the screening age group occurs in other markets, it is expected that the current global addressable market will also increase considerably.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »